RxDoctor Payments Data

Thomas Hwang, MD

Internal Medicine · Tustin, CANPI 1124039722

Payments from drug & device makers

$2,190in general payments, 2019–2025

Across 97 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$486
  • Lilly USA, LLC$346
  • AstraZeneca$251
  • Amgen$213
  • Merck$173
  • Pfizer$135
  • plus $585 from 14 others

What the payments were for

  • Food & beverage$2,190100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,190 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$185,693
Medicare patients
371
Services billed
1,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin55$68,579
EliquisApixaban55$53,512
TradjentaLinagliptin44$43,206
GlyxambiEmpagliflozin/Linagliptin25$39,588
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$22,645
JanuviaSitagliptin Phosphate13$17,562
MyrbetriqMirabegron23$16,502
XareltoRivaroxaban21$11,970
LivaloPitavastatin Calcium12$11,459
Breo ElliptaFluticasone/Vilanterol29$9,477
LipitorAtorvastatin Calcium11$5,967
Atorvastatin Calcium499$5,966
MultaqDronedarone Hcl12$4,967
Valsartan141$3,959
Levothyroxine Sodium224$3,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$486$151,373124 claims
PfizerEliquis, Lipitor, Paxlovid$135$60,84686 claims
GSKTrelegy Ellipta, Breo Ellipta$88$32,12262 claims
MerckJanuvia$173$17,56213 claims
Johnson & JohnsonXarelto$99$11,97021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Tustin

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →